anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses immersion bath liquid medicine for treating rheumatoid and provides external-use traditional Chinese medicine which is good in curative effect, quick in action, free of toxic and side effects and capable of treating the rheumatoid. The immersion bath liquid medicine is prepared by, by weight, 45-60 parts of pine needle, 41-49 parts of Laportea bulblfera (Sieb.etZucc.) Wedd. root, 30-38 parts of willow bark, 38-50 parts of white mulberry root bark, 50-60 parts of China creeper root, 45-60 parts of Chinese prickly ash root, 50-70 parts of ramie root, 30-70 parts of erycibe obtusifolia, 40-75 parts of radix cyathulae, 40-60 parts of uncaria and water, wherein the weight of the water is 190 times that of the medicinal raw materials. A preparation method of the immersion bath liquid medicine includes: soaking the uncaria with part of the water for 90-150 minutes, and filtering to obtain filtrate and soaked uncaria for standby; soaking the rest of medicinal raw materials in the rest of water for 90-150 minutes, adding the filtrate, heating to 90-110 DEG C, preserving the temperature for 50-70 minutes, adding the uncaria for standby, and continuing the temperature preservation for 25-30 minutes. The immersion bath liquid medicine for treating the rheumatoid is capable of promoting blood circulation to remove blood stasis, activating channels and collaterals, inducing resuscitation and acting on bones, dispelling wind and cold, promoting local blood circulation and strengthening and consolidating body resistance.
PURPOSE:To provide an antiarteriosclerotic agent effective to prevent the deposition of lipid to arterial wall and containing 3,5-bis(phenylmethyl)-tetrahydro-2 H-1,3,5-thiadiazine-2-thi-one known as a feed additive and mildewproofing agent. CONSTITUTION:The objective antiarteriosclerotic agent can be produced by using the compound of formula as an active component. The compound is effective to prevent the deposition of lipid to the arterial wall and has low acute toxicity and high safety. It is useful as a preventive and remedy for ischemic circulatory diseases (e.g. cardiac infraction, stenocardia, hypertension, thrombosis, etc.). It is administered preferably orally at a dose of preferably 0.1-1.5g daily.
Dizziness or drowsiness may occur after the first dose of this medicine. Avoid driving or performing hazardous tasks for the first 24 hours after taking this medicine or when the dose is increased.  
  


Dizziness, lightheadedness, or fainting may occur, especially when rising from a lying or sitting position. Getting up slowly may help lessen the problem. These effects may also occur if you drink alcohol, stand for long periods of time, exercise, or if the weather is hot. While taking Prazosin hydrochloride capsules, be careful in the amount of alcohol you drink. Also, use extra care during exercise or hot weather, or if standing for long periods. Check with your physician if you have any questions.
Commercial lactose-free kefir (Altinkilic, Turkey) beverage, which is produced from cow milk with 3.1% fat and 7.5% protein content and stored in appropriate conditions, was used in this study. The kefir (intervention) group was provided with 250 mL of plain lactose-free kefir containing at least 107-1010 probiotic bacterial strains (Lactobacillus, Lactic acid, Streptococcus, Acetic acid bacteria sp) and yeasts (Kluyveromyces marxianus, Torulaspora delbrueckii, Saccharomyces cerevisiae, Candida). The participants were asked to consume 250 mL of plain lactose-free kefir daily for 6 weeks. Any particular time was not specified for kefir consumption. Kefir consumption routine of participants was followed up by regular phone calls every week and evaluated by examining their consumption records.
To provide: a carboxamide derivative having reduced content of amide ester; a method for producing thereof; and a detergent composition containing the carboxamide derivative and having excellent low-temperature stability. One method for producing a carboxamide derivative is to react carboxamide, produced with a manufacturing method of carboxamide including 0.02% by weight to 0.18% by weight of amide ester, with hydrogen peroxide, wherein the method includes a carboxamide synthesis process to synthesize carboxamide by reacting diamine with fatty acid ester at a molar rate of 1.20 to 1.60. Another method for producing a carboxamide derivative is to react the carboxamide with monohaloalkylcarboxylic acid or a salt thereof. A carboxamide derivative is produced by the method for producing a carboxamide derivative. A detergent composition includes the carboxamide derivative. The carboxamide derivative is preferably amidoamine oxide or amide betaine.
MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
The invention discloses a traditional Chinese medicine for improving immunity for cold prevention and treatment. The traditional Chinese medicine is obtained by repeated research and experiment according to the Chinese and western medicine theory, is subjected to the human body test, has clear curative effects and relates to the field of medical science. The traditional Chinese medicine comprises 1 part of ginseng, 2 parts of north acanthopanax root, 2 parts of Ningxia wolfberry, 2 parts of radix astragali, 2 parts of bighead atractylodes rhizome, 1 part of divaricate saposhnikovia root and 1 part of Chinese magnoliavine. The traditional Chinese medicine is mainly used for people having susceptibility to cold or people suffering from cold. A clinical practice proves that the traditional Chinese medicine has the following characteristics comprising that 1, the traditional Chinese medicine has obvious immunity improvement effect and can reduce cold generation, 2, the human body pathological process is adjusted so that the human body tends to normalization, 3, the effect of improving human body immunity to nonspecific stimulation is obtained, 4, the effect of enhancing physique is obtained, 5, the effects of reducing blood fat and blood pressure are obtained, 6, theoretically, the effects of resisting tumors, delaying tumor generation and inhibiting tumor transfer are obtained, and 7, the traditional Chinese medicine is a pure traditional Chinese medicine preparation and has no toxic or side effect at present. The traditional Chinese medicine has the characteristics of novelty, scientificity, applicability and economy.
PURPOSE:To obtain the titled porcelain material resistant to yellowing phenomenon in the baking of the porcelain material on a porcelain-baking alloy composed mainly of a silver-containing palladium without considerably varying the physical properties of the porcelain material, by including a nitric acid compound into a baking porcelain for dental use. CONSTITUTION:Total or a part of a principal composition constituting a baking porcelain material for dental use, e.g. opaque, body, incisal or translucent is surface-treated with an aqueous solution of a nitric acid compound and dried. As an alternative method, said porcelain material is mixed with 0.2-2.0wt.% of an insoluble or scarcely soluble nitric acid compound to include the nitric acid compound into the porcelain material. An artificial dental crown having a color tone close to that of natural tooth can be produced with normal operation by the above process. The obtained artificial dental crown is resistant to the yellowing phenomenon (yellow discoloration) caused by silver and developed in the application and baking of the porcelain material on an inexpensive and easily solderable porcelain-baking alloy composed mainly of a silver-containing palladium without considerably varying the physical properties of the porcelain material.
Azilsartan medoxomil

Edarbyclor can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Edarbyclor as soon as possible [see Use in Specific Populations (8.1)]. 

Chlorthalidone

Thiazides cross the placental barrier and appear in cord blood. Adverse reactions include fetal or neonatal jaundice and thrombocytopenia.
PROBLEM TO BE SOLVED: To obtain an antichlamidial agent which shows antimicrobial effect, e.g. detergency, disinfection or the like, on chlamidia, exhibits increased antimicrobial effect on chlamidia particularly before or just after infection and exerts excellent infection prophylactic effect or detergent effect. SOLUTION: This antichlamidial agent is obtained by including an extract obtained by using a bamboo, e.g. Phyllostachys pubescens or the like, and an alcohol or ether as an extraction raw material and an extracting solvent, respectively, as an active ingredient. This antichlamidial agent contains benzoquinone in the extract, increases the infection preventive effect of somatic cells on infectious elementary bodies(EB) in the life cycle of chlamidia and exhibits a certain antimicrobial effect due to annihilating intracellular reticular bodies(RB). Further, the more certain antimicrobial effect is exhibited when the extract contains liquid benzoquinone in a formation amount of 0.2-5 vol.%.
Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4. The preferred composition also includes a cation exchange material such as sulfonated ion exchange resin as an admixture which, when combined with the ferrate (VI) salt, will hydrate in the presence of blood or other aqueous media to produce Fe+++, thereby promoting clotting of the blood and body fluid and to produce oxygen. The cation exchange material produces a scab or protective coating over the wound for protection and enhanced healing. Oxygen produced during the reaction substantially reduces the level of bacteria, virus and fungus at the wound. The compound must be stored dry unmixed together and mixed into a paste with the victim's blood or other aqueous media just prior to its application to the wound.
The intervention is an 16-hour classroom-based relationship education program taught by project staff. This instruction will strengthen and promote healthy marriages among young refugees and immigrants through education and comprehensive case management that will support an overall goal of helping youth build healthy relationship skills while supporting positive socio-emotional development and promoting successful transitions to young adulthood.
The efficacy of ULORIC was demonstrated in three randomized, double-blind, controlled trials in patients with hyperuricemia and gout. Hyperuricemia was defined as a baseline serum uric acid level ≥ 8 mg per dL.

Study 1 randomized patients to: ULORIC 40 mg daily, ULORIC 80 mg daily, or allopurinol (300 mg daily for patients with estimated creatinine clearance (Clcr) ≥ 60 mL per min or 200 mg daily for patients with estimated Clcr ≥ 30 mL per min and ≤ 59 mL per min). The duration of Study 1 was 6 months. 

Study 2 randomized patients to: placebo, ULORIC 80 mg daily, ULORIC 120 mg daily, ULORIC 240 mg daily or allopurinol (300 mg daily for patients with a baseline serum creatinine ≤ 1.5 mg per dL or 100 mg daily for patients with a baseline serum creatinine greater than 1.5 mg per dL and ≤ 2 mg per dL). The duration of Study 2 was 6 months.

Study 3, a 1-year study, randomized patients to: ULORIC 80 mg daily, ULORIC 120 mg daily, or allopurinol 300 mg daily. Subjects who completed Study 2 and Study 3 were eligible to enroll in a phase 3 long-term extension study in which subjects received treatment with ULORIC for over three years.

In all three studies, subjects received naproxen 250 mg twice daily or colchicine 0.6 mg once or twice daily for gout flare prophylaxis. In Study 1 the duration of prophylaxis was 6 months; in Study 2 and Study 3 the duration of prophylaxis was 8 weeks.

The efficacy of ULORIC was also evaluated in a 4 week dose ranging study which randomized patients to: placebo, ULORIC 40 mg daily, ULORIC 80 mg daily, or ULORIC 120 mg daily. Subjects who completed this study were eligible to enroll in a long-term extension study in which subjects received treatment with ULORIC for up to five years.

Patients in these studies were representative of the patient population for which ULORIC use is intended. Table 2 summarizes the demographics and baseline characteristics for the subjects enrolled in the studies.

Serum Uric Acid Level less than 6 mg per dL at Final Visit:  ULORIC 80 mg was superior to allopurinol in lowering serum uric acid to less than 6 mg per dL at the final visit. ULORIC 40 mg daily, although not superior to allopurinol, was effective in lowering serum uric acid to less than 6 mg per dL at the final visit (Table 3).

In 76% of ULORIC 80 mg patients, reduction in serum uric acid levels to less than 6 mg per dL was noted by the Week 2 visit. Average serum uric acid levels were maintained at 6 mg per dL or below throughout treatment in 83% of these patients. 

In all treatment groups, fewer subjects with higher baseline serum urate levels (≥ 10 mg per dL) and/or tophi achieved the goal of lowering serum uric acid to less than 6 mg per dL at the final visit; however, a higher proportion achieved a serum uric acid less than 6 mg per dL with ULORIC 80 mg than with ULORIC 40 mg or allopurinol. 

Study 1 evaluated efficacy in patients with mild to moderate renal impairment (i.e., baseline estimated Clcr less than 90 mL per minute). The results in this sub-group of patients are shown in Table 4.
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a challenging condition to treat with myocardial fibrosis being a pivotal pathological component. Previous studies have suggested a role for inducible nitric oxide synthase (iNOS) in the progression of this condition, but the precise mechanisms remain unclear. This study aimed to investigate the role of iNOS in HFpEF-related myocardial fibrosis and identify potential therapeutic targets.
METHODS: A 'two-hit' mouse model of HFpEF was established, and echocardiography, histopathology and biochemical analyses were performed. In vitro experiments were conducted in mouse cardiac fibroblasts, with iNOS overexpression and application of iNOS or phosphatidylinositol 3 kinase (PI3K) inhibitors. The iNOS-S-nitrosylated phosphatase and TENsin homolog (SNO-PTEN)-phosphorylated-protein kinase B (p-AKT) pathway was investigated, along with the effects on fibrotic markers and cell proliferation and migration.
RESULTS: HFpEF mice exhibited significant cardiac dysfunction and fibrosis, with increased expression of iNOS, SNO-PTEN, and p-AKT, indicative of the activation of the iNOS-SNO-PTEN-p-AKT pathway. iNOS overexpression in mouse cardiac fibroblasts led to increased SNO-PTEN, decreased PTEN, activated phosphorylated PI3K (p-PI3K) and p-AKT, and enhanced cell proliferation and migration, as well as increased collagen I and III expression. The use of an iNOS inhibitor (L-NIL) or a PI3K inhibitor (LY294002) partially reversed these changes.
CONCLUSION: Our findings suggest that the iNOS-SNO-PTEN-p-AKT pathway may play a crucial role in HFpEF-related myocardial fibrosis, with iNOS and PI3K inhibitors offering potential therapeutic benefits. These insights may pave the way for the development of effective drug therapies for HFpEF.
A system (10) and method (70) for medical audit is provided. Modules each regarding a different patient status are maintained. A chatbot is activated and a status of a patient is received (42). One of the modules for the patient is selected (43) based on the patient status. Requests for information are provided (44) to the patient based on the selected module and information from the patient is received (45) in response to the requests. The information is checked for compliance (82) with a set of standards selected for the information and the patient is notified (76) that the information does not comply.
The present invention discloses a wild vegetable juice beverage and a preparation process thereof. The wild vegetable juice beverage is prepared from tender stem leaves of acanthopanax, tender stem leaves of aralia elata(Miq.)seem, white granulated sugar, citric acids, pectase, flavoring and water. The preparation process comprises: the selected tender stem leaves of acanthopanax and aralia elata(Miq.)seem are pulverized with a machine and then treated by enzymolysis with pectase; the pulverized tender stem leaves of acanthopanax and aralia elata(Miq.)seem after enzymolysis are soaked for 4 to 12 hours to obtain vegetable juice leaching liquor; the leaching liquor after filtration is treated at low temperature below 8DEGC for 24 hours and then thermally treated at the temperature of 60DEGC for 4 hours; the leaching liquor is filtered and diluted with water; ingredients of white granulated sugar, citric acids and flavoring are proportionally added to the diluted leaching liquor to obtain a mixture; the mixture is filtered, filled, sterilized, treated by quality inspection and packaged to obtain the finished product of the wild vegetable juice beverage. The wild vegetable juice beverage contains multiple vitamins and microelements beneficial for human bodies, has the characteristics of low cost and high nutritive value and is a pollution-free pure green beverage.
0.9% Sodium Chloride Irrigation, USP is a sterile nonpyrogenic, isotonic solution in a single dose ARTHROMATIC plastic container for use as an arthroscopic irrigating solution. Each liter contains 9 g Sodium Chloride, USP (NaCl) in Water for Injection. pH 5.5 (4.5 to 7.0). Milliequivalents per liter: Sodium - 154, Chloride - 154. Osmolarity 308 mOsmol/L (calc.). No antimicrobial agent has been added.

The ARTHROMATIC plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexylphthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
PURPOSE: To evaluate the relative diagnostic yield of clinical germline genomic tests in a diverse pediatric cancer population.
PATIENTS AND METHODS: The KidsCanSeq study enrolled pediatric cancer patients across six sites in Texas. Germline analysis included both exome sequencing and a therapy-focused pediatric cancer gene panel. The results were categorized by participants demographics, the presence of pathogenic or likely pathogenic (P/LP) variants, and variants of uncertain significance (VUS) in cancer predisposition genes (CPGs). Pediatric actionable CPGs were defined as those with cancer surveillance recommendations during childhood.
RESULTS: Cancer P/LP variants were reported by at least one platform in 103 of 578 (17.8%) participants of which 76 were dominant cancer genes (13.1%) with no significant differences by self-described race or Hispanic ethnicity. However, the proportion of participants with VUS was greater in Asian and African American participants (P = .0029). Diagnostic yield was 16.6% for exome versus 8.5% for panel (P < .0001) with 42 participants with concordant germline results. Exome-only results included P/LP variants in 30 different CPGs in 54 participants, whereas panel-only results included seven participants with a copy number or structural P/LP variants in CPGs. There was no significant difference in diagnostic yield limited to pediatric actionable CPGs (P = .6171).
CONCLUSION: Approximately 18% of a diverse pediatric cancer population had germline diagnostic findings with 50% of P/LP variants reported by only one platform because of CPGs not on the targeted panel and copy number variants (CNVs)/rearrangements not reported by exome. Although diagnostic yields were similar in this diverse population, increases in VUS results were observed in Asian and African American populations. Given the clinical significance of CNVs/rearrangements in this cohort, detection is critical to optimize germline analysis of pediatric cancer populations.